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Journal of the American Heart Association
SYSTEMATIC REVIEW AND META-ANALYSIS

Coronary Revascularization Versus Optimal
Medical Therapy in Renal Transplant
Candidates With Coronary Artery Disease:
A Systematic Review and Meta-Analysis
Muhammad U. Siddiqui

, MD, MS; Joey Junarta

, MBBS; Gregary D. Marhefka, MD

BACKGROUND: Coronary artery disease (CAD) is highly prevalent in patients with chronic kidney disease and is a common
cause of mortality in end-stage renal disease. Thus, patients with end-stage renal disease are routinely screened for CAD
before renal transplantation. The usefulness of revascularization before transplantation remains unclear. We hypothesize that
there is no difference in all-cause and cardiovascular mortality in waitlisted renal transplant candidates with CAD who underwent revascularization versus those treated with optimal medical therapy before transplantation.
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METHODS AND RESULTS: This meta-analysis was reported according to the Preferred Reporting Items for Systematic Review
and Meta-Analyses guidelines. MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials were systematically
searched to identify relevant studies. Risk of bias was assessed using the modified Newcastle-Ottawa Scale and Cochrane
risk of bias tool. The primary outcome of interest was all-cause mortality. Eight studies comprising 945 patients were included
(36% women, mean age 56 years). There was no difference in all-cause mortality (risk ratio [RR], 1.16 [95% CI, 0.63–2.12),
cardiovascular mortality (RR, 0.75 [95% CI, 0.29–1.89]), or major adverse cardiovascular events (RR, 0.78 [95% CI, 0.30–2.07])
when comparing renal transplant candidates with CAD who underwent revascularization versus those who were on optimal
medical therapy before renal transplant.
CONCLUSIONS: This meta-analysis demonstrates that revascularization is not superior to optimal medical therapy in reducing
all-cause mortality, cardiovascular mortality, or major adverse cardiovascular events in waitlisted kidney transplant candidates
with CAD who eventually underwent kidney transplantation.
Key Words: coronary artery disease ■ coronary revascularization ■ medical therapy ■ renal transplantation

C

ardiovascular disease is a leading cause of morbidity and mortality among patients with end-
stage renal disease. Kidney transplant candidates
are at high risk for adverse cardiovascular events, despite already having undergone cardiovascular evaluation to be listed for transplantation.1,2 The cumulative
incidence of myocardial infarction (MI) has been shown
to range from 9% to 17% by 3 years after transplant listing, and from 5% to 11% after kidney transplantation.3,4

Cardiovascular disease is the most common cause of
death in kidney transplant recipients with functioning
allografts, accounting for 30% of overall mortality, with
highest rates in the peritransplant period.5
Because of this, transplant candidates are routinely
screened for asymptomatic coronary artery disease
(CAD). The goal is to identify and correct undiagnosed
CAD to prevent premature cardiovascular mortality at
transplantation or soon after. Occasionally, investigated
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CLINICAL PERSPECTIVE
What Is New?

• Our meta-
analysis demonstrates that coronary revascularization is not superior to optimal
medical therapy in reducing all-cause mortality,
cardiovascular mortality, or major adverse cardiovascular events in waitlisted kidney transplant
candidates with coronary artery disease who
eventually underwent kidney transplantation.

What Are the Clinical Implications?

• Our findings suggest that asymptomatic kidney transplant candidates with coronary artery
disease should not undergo routine coronary
revascularization exclusively to reduce perioperative cardiovascular events.

Nonstandard Abbreviations and Acronyms
MACE
OMT

major adverse cardiovascular event
optimal medical therapy

Downloaded from http://ahajournals.org by on March 1, 2022

patients are deemed unsuitable for transplant because
of unmodifiable cardiac risk and poor prognosis. Such
patients are subsequently removed from the waitlist.
Currently, there is no established protocol to determine
the optimal strategy to monitor and maintain cardiac
fitness in waitlisted patients. Critically, whether abnormal screening results warrant further invasive investigation, such as coronary angiography and subsequent
revascularization, is unclear.
The objective of this meta-analysis was to compare
the usefulness of coronary revascularization versus
medical management before transplantation in improving hard outcomes in renal transplant recipients
with CAD. Our hypothesis is that there would be no
difference in outcomes in transplant candidates with
CAD who underwent revascularization versus those
treated with optimal medical therapy (OMT) alone before transplantation.

METHODS
Data are safely kept in a password-protected security system at Thomas Jefferson University Hospital.
The data sets used and/or analyzed during the current study are deidentified and available from the corresponding author on reasonable request.
All procedures performed in studies involving
human participants were in accordance with the ethical
standards of the institutional and/or national research

committee and with the 1964 Helsinki Declaration and
its later amendments or comparable ethical standards.
The study was a meta-analysis that did not require approval from our institutional review board. This article
does not contain any studies with animals performed
by any of the authors.

Data Sources and Search Strategy
This systematic review and meta-
analysis was reported according to the Preferred Reporting Items for
Systematic Review and Meta-
Analyses guidelines.6
MEDLINE, Scopus, and Cochrane Central Register of
Controlled Trials were searched from database inception through June 2021 using the following combination of keywords: coronary artery disease OR heart
disease OR CAD OR coronary disease AND renal
transplant OR kidney transplant. No time restriction
was placed on the search. However, language was
restricted to English. We also searched trial registries
(eg, www.clinicaltrialresults.org, www.clinicaltrials.gov),
abstracts, and presentations from major cardiovascular proceedings. All citations retrieved from the search
were transferred to EndNote X7.5 (Thompson ISI
ResearchSoft, Philadelphia, PA) Reference Manager,
and duplicates were removed.

Study Selection
All citations were screened by one reviewer (M.U.S.).
Eligible studies reported outcomes in renal transplant
candidates who underwent revascularization for CAD
versus medical therapy alone for CAD before transplant. We included randomized and nonrandomized
studies. Exclusion criteria included studies that focused on screening for CAD in renal transplant candidates without studying the effects of treatment strategy
on outcomes.
The main outcomes of interest were all-cause mortality, cardiovascular mortality, and major adverse
cardiovascular events (MACEs), which included MI,
acute coronary syndrome, heart failure, and ventricular
arrythmias.

Data Extraction and Risk of Bias
Two independent reviewers (M.U.S. and J.J.) extracted
the data on year of publication, study design, inclusion
criteria, primary end points, and follow-up time using
a standardized data extraction form. Risk of bias was
assessed using the modified Newcastle-Ottawa Scale
for observational studies, which assesses 3 domains:
patient selection, comparability, and outcome assessment.7 For randomized controlled trials, the Cochrane
risk of bias tool was used.8 The methodological quality
of a study was graded as high or low based on whether
the study had adequate adjustment for confounders,
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which we judged to be the most critical domain affecting the main outcomes of interest.9

Statistical Analysis
We extracted or calculated a risk ratio (RR) and 95%
CI from each study. RRs were pooled using a random-
effects model to account for between-study variance.10
The I2 statistic was quantified to measure heterogeneity with values >25%, 50%, and 75% consistent with
low, moderate, and high degrees of heterogeneity, respectively.11 Review Manager software version 5.4 was
used for analysis. P<0.05 was considered statistically
significant. Certainty in the evidence (ie, confidence in
the final estimates) was assessed using the Grades of
Recommendation, Assessment, Development, and
Evaluation approach based on the risk of bias, imprecision, indirectness, inconsistency, and publication bias.12
The authors had full access to all the data in the study and
take responsibility for its integrity and the data analysis.

RESULTS
Study Selection
Of 728 potential articles screened, 8 studies comprising 945 patients were included (Figure 1). Table 1 summarizes the characteristics of included studies.13–20
Of these, 481 patients underwent revascularization
for CAD before renal transplant, and 464 patients received OMT alone. All the studies were observational
(nonrandomized), except for Herzog et al, which was
a randomized controlled trial.20 The studies did not
report the medications used to provide OMT. Table 2
summarizes the baseline characteristics of included
patients. Out of 945 patients included in this analysis,
339 were women (35.9%). The data on number of female patients participating in the studies performed by
Lindley et al, Tita et al, and Eschertzhuber et al could
not be obtained.14,17,19 The mean age of patients who
underwent revascularization was 56.5 years, whereas
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Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram
of included studies.
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Retrospective cohort
study

Retrospective cohort
study

Prospective cohort
study

Retrospective cohort
study

Retrospective cohort
study

Randomized
controlled trial

Felix et al15

Kahn et al16

Lindley et al17

Singh et al18

Tita et al19

Herzog et al20

ESRD indicates end-stage renal disease.

Retrospective cohort
study

Prospective cohort
study

Design

Eschertzhuber et al14

De Lima et al

Study

Dialysis and nondialysis
patients with ESRD waiting
to receive kidney graft

Dialysis and nondialysis
patients with ESRD
who received kidney
transplantation

Patients with diabetes with
ESRD who received kidney
transplantation

Patients with ESRD waiting
to receive kidney graft

Dialysis and nondialysis
patients with ESRD
who received kidney
transplantation

Dialysis and nondialysis
patients with ESRD
who received kidney
transplantation

Patients with ESRD
who received kidney
transplantation

Hemodialysis patients with
ESRD waiting to receive
their first kidney graft

Population

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(percutaneous) plus medical
treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Coronary revascularization
before kidney transplantation
(surgical or percutaneous) plus
medical treatment

Experimental arm
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Table 1. Characteristics of Included Studies

Medical treatment

Medical treatment

Medical treatment

Medical treatment

Medical treatment

Medical treatment

Medical treatment

Medical treatment

Control arm

Primary outcome: composite of
nonfatal myocardial infarction
and all-cause mortality;
secondary outcomes:
composite of death, nonfatal
myocardial infarction, stroke,
or hospitalization for unstable
angina, heart failure, or
resuscitated cardiac arrest

Cardiac events (coronary
revascularization, nonfatal
myocardial infarction, heart
failure, cardiovascular mortality)
and cerebrovascular events

Cardiac events (myocardial
infarction, ventricular
arrhythmia, heart failure),
cardiovascular mortality, and
all-cause mortality

Graft failure, revascularization,
nonfatal myocardial infarction,
stroke, and all-cause mortality

All-cause mortality

Primary outcome: composite
of cardiovascular mortality,
acute coronary syndrome, and
coronary revascularization after
renal transplantation; secondary
outcome: components of the
primary outcome, incident
angina, incident heart failure,
and all-cause mortality

Early or late postoperative
death, myocardial infarction,
other posttransplant cardiac
event

Cardiac events (composite of
myocardial infarction, unstable
angina, sudden death) and all-
cause mortality

End points

3y

2.85 y

1y

1y

5y

5.6 y

3y

Patients were followed up
until death or a coronary
event. There was no
mention of the mean
or median duration of
follow-up.

Follow-up duration
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60.0 (13.0)

29 (median)

56.8 (8.7)

13 (27%)

20 (41%)

36 (73%)

32 (65%)

21 (43%)

37 (76%)

57.0 (13.0)

22 (median)

Age, y, mean (SD) or
median (IQR)

Women, n (%)

Smoking history, n (%)

Hypertension, n (%)

Diabetes, n (%)

Dyslipidemia, n (%)

Coronary artery
disease, n (%)

LVEF %, mean (SD) or
median (IQR)

Time on dialysis, mo,
mean (SD) or median
(IQR)

NR

NR

β-Blocker use, n (%)

ACEi or ARB, n (%)

Antiplatelet agent, n (%)

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

7

NR

NR

67 (75%)

38 (43%)

NR

NR

89 (100%)

77 (87%)

81 (91%)

81 (91%)

NR

22 (25%)

58.1 (9.3)

89

Revascul
arization

NR

NR

134 (65%)

62 (30%)

NR

NR

207 (100%)

141 (68%)

181 (87%)

176 (85%)

NR

65 (31%)

56.0 (10.7)

207

Medical

78 (83%)

50 (54%)

NR

68 (73%)

24 (12–60)

58 (60–61)

11 (12%)

NR

59 (63%)

82 (92%)

49 (52%)

25 (27%)

59 (54–64)

94

Revascul
arization

94 (94%)

39 (39%)

NR

76 (76%)

24 (12–36)

60 (52–65)

14 (14%)

NR

55 (55%)

92 (92%)

54 (54%)

24 (24%)

61 (53–65)

100

Medical

Herzog et al20

132 (73%)

75 (41%)

130 (71%)

106 (58%)

109
(42–161)

NR

158 (87%)

120 (66%)

121 (66%)

178 (98%)

57 (31%)

43 (24%)

64 (57–69)

182

Revascul
arization

Kahn et al16

18 (58%)

7 (23%)

15 (48%)

10 (32%)

116 (62–191)

NR

17 (55%)

18 (58%)

22 (71%)

27 (87%)

9 (29%)

9 (29%)

62 (50–72)

16

Medical‡

NR

NR

NR

NR

NR

NR

109 (16%)

280 (41%)

252 (37%)

574 (84%)

43 (6%)

299 (44%)

48.0 (15.0)

19

Revascul
arization
3

Medical

Lindley et al17*

32 (100%)

7 (22%)

27 (84%)

23 (72%)

NR

50.0 (15.2)

23 (72%)

NR

32 (100%)

30 (94%)

6 (19%)

13 (40%)

57.0 (8.3)

32

Revascul
arization

Singh et al18

35 (100%)

11 (31%)

23 (66%)

24 (67%)

NR

50.0 (12.8)

20 (57%)

NR

35 (100%)

30 (86%)

12 (34%)

9 (26%)

54.0 (9.8)

35

Medical

NR

NR

NR

NR

NR

NR

16 (11%)

89 (60%)

97 (65%)

143 (96%)

NR

70 (47%)

53.4 (11.0)

1

Revascul
arization

Tita et al19†

9

Medical

ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; IQR, interquartile range; LVEF, left ventricular ejection fraction; and NR, not reported.
*Baseline characteristics of all included patients (n=685) at study recruitment, including those not transplanted. Baseline characteristics stratified by whether patients were revascularized vs medically managed
alone before transplantation were not reported.
†
Baseline characteristics of all included patients (n=149) at study recruitment. Baseline characteristics stratified by whether patients were revascularized vs medically managed alone before transplantation were not
reported.
‡
Baseline characteristics of all included patients (n=31) in the medical therapy group at study recruitment, including those not having significant coronary artery disease. Baseline characteristics of patients with
significant coronary artery disease medically managed before transplantation were not separately reported.

NR

NR

NR

NR

NR

NR

Statin use, n (%)

39 (45%)

31 (36%)

56 (64%)

77 (89%)

32 (37%)

26 (30%)

59.1 (8.6)

87

15

49

No. of patients

Medical

Revascul
arization

Revascul
arization

Study

Medical

Eschertzhuber et al14

De Lima et al13

Felix et al15
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Table 3. Risk of Bias Assessment of the Included Observational Studies
Studies
Modified Newcastle-
Ottawa Scale

De Lima
et al13

Eschertzhuber
et al14

Felix et al15

Kahn et al16

Lindley et al17

Singh et al18

Tita et al19

Selection

4

4

4

4

4

4

4

Comparability

2

0

1

2

0

1

1

Adjustment

Adjusted

Unadjusted

Adjusted

Adjusted

Unadjusted

Adjusted

Adjusted

Outcome

2

3

3

3

2

2

3

Total, maximum
score=9

8

7

7

9

6

7

8

For selection, the highest score was 4 based on the representativeness of the exposed cohort, selection of the nonexposed cohort, ascertainment of the
exposure, and outcome of interest at the start of the study. For comparability, the highest score was 2 based on comparability of the cohort. For outcome, the
highest score was 3 based on assessment of the outcome, follow-up period, and adequacy of the follow-up period.

the mean age of patients who received OMT alone was
56.1 years. Mean follow-up duration was 3.1 years.
Tables 3 and 4 show the risk of bias assessment.
There was high risk of selection bias and performance
bias in the 7 observational studies included because of
lack of randomization and blinding. Overall, the risk of
detection bias, reporting bias, and attrition bias was low
among all studies. We were unable to statistically evaluate publication bias because of the small number of included studies.

Outcomes
Downloaded from http://ahajournals.org by on March 1, 2022

Outcomes in renal transplant candidates with CAD who
underwent revascularization versus those who received
OMT alone before renal transplantation were compared.
Five studies reported all-
cause mortality, and pooled
results found no difference between groups (RR, 1.16
[95% CI, 0.63–2.12]) (Figure 2). Four studies reported
cardiovascular mortality and pooled results and found
no difference between groups (RR, 0.75 [95% CI, 0.29–
1.89]) (Figure 3). Six studies reported MACEs, and
pooled results found no difference between groups (RR,
0.78 [95% CI, 0.30–2.07]) (Figure 4).

Sensitivity Analysis
The sensitivity analysis of the pooled findings after the
exclusion of the unadjusted data from the studies by
Eschertzhuber et al and Lindley et al showed results
consistent with the overall risk of MACEs (RR, 1.23
[95% CI, 0.53–2.88]) (Figure 5).14,17 The pooled results
from the unadjusted studies favored revascularization, and the result was statistically significant (RR,
0.07 [95% CI, 0.01–0.55]). This contrasting result was
likely because of the small sample size and increased
Table 4.

confounding in the unadjusted studies. The χ2 test for
subgroup differences was significant (P=0.01).6

Certainty in the Estimates
All studies included were observational except the
study by Herzog et al.20 Thus, these studies had variable methodological quality and are at increased risk
of selection and confounding bias. The estimates were
not precise for the 3 reported outcomes because of a
smaller number of events. There was no indirectness
or evidence of publication bias. Heterogeneity was
noted among the included studies. The quantified I2
value for each individual outcome investigated are as
follows: all-
cause mortality 68% (moderate), cardiovascular mortality 35% (moderate), and MACEs 67%
(moderate). Overall, the certainty in the estimates in all
the outcomes was judged to be low.

DISCUSSION
Screening for cardiovascular disease in kidney transplant candidates may be important for 2 reasons. First,
screening is important to identify those with asymptomatic CAD to enable revascularization or removal of the
patient from the waitlist, with the end goal of preventing premature cardiovascular mortality at transplantation or soon after. Second, screening is also important
to avoid the misallocation of scarce donor allografts
into those who experience early mortality. It is unclear
whether coronary revascularization is superior to medical therapy in correcting CAD in this patient population.
This meta-analysis demonstrated no difference in all-
cause mortality, cardiovascular mortality, or MACEs in
renal transplant recipients with CAD who underwent

Cochrane Risk of Bias Tool for Randomized Controlled Trials

Reference
Herzog et al

20

Sequence
generation

Allocation
concealment

Blinding
participants

Blinding
assessors

Incomplete
outcome data

Selective
reporting

Other bias

Yes

Yes

Yes

Yes

All patients were
accounted for

No

None
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Figure 2. Forest plot for all-cause mortality comparing revascularization vs medical therapy.
The pooled risk ratio with 95% CI were calculated using a random-effects model. Weight refers to the contribution of each study to the
pooled estimate. Squares and horizontal lines denote the point estimate and 95% CI for each study’s risk ratio. The diamond signifies
the pooled risk ratio, the diamond center denotes the point estimate, and the width denotes the 95% CI. IV indicates inverse; and
OMT, optimal medical therapy.
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revascularization versus patients who were on OMT
alone before renal transplantation.
Our findings agree with the meta-
analysis conducted by Kamran et al.21 They found no difference in
cardiovascular mortality in those treated with OMT versus coronary revascularization for CAD before transplantation. However, only 6 studies were included in
their analysis, and notable outcomes such as all-cause
mortality and MACEs were not assessed. Additionally,
information on the risk of bias and certainty in the estimates of included studies were not reported. Finally,
a sensitivity analysis after exclusion of the unadjusted
data was not conducted. A separate meta-
analysis
consisting of 3 randomized controlled trials conducted
by Farkouh et al also reported similar findings to our
study.22 In this study, strategies of coronary artery bypass graft surgery with OMT, percutaneous coronary
intervention with OMT, or OMT alone were compared
in a group of patients with chronic kidney disease
(CKD) and concomitant diabetes and stable ischemic
heart disease. There was no difference in the primary
composite outcome of all-cause mortality, nonfatal MI,
and nonfatal stroke when comparing OMT alone versus coronary artery bypass graft surgery with OMT or
percutaneous coronary intervention with OMT. In contrast to our study, included patients all had diabetes

and were not exclusively kidney transplant candidates.
Thus, posttransplant outcomes were not investigated.
There are other notable studies that have investigated preemptive revascularization in kidney transplant candidates and those with end-
stage renal
disease. Kumar et al evaluated the usefulness of an
aggressive approach to invasive cardiac investigations
during transplant evaluation.23 Their practice involved
performing screening coronary angiography on all
potential transplant recipients who were over the age
of 50 years, those with diabetes, those with cardiac
symptoms or disease, and those with an electrocardiogram showing changes suggestive of ischemia or
previous MI. Subsequent revascularization was at the
discretion of a single cardiologist. In that study, 168
of 657 patients underwent revascularization. Overall
survival 3 years after revascularization was 83.5%, versus 91.5% in those who were not intervened. Cardiac
event-free survival 3 years after revascularization was
86.8%, versus 95.1% in those who were not intervened. These comparisons were made regardless of
whether patients were transplanted or not. Exclusive
posttransplant outcomes between groups were not
compared. In the study by Hemmelgarn et al, data
on 41 786 patients were captured on all patients undergoing cardiac catheterization in Alberta, Canada

Figure 3. Forest plot for cardiovascular mortality comparing revascularization vs medical therapy.
The pooled risk ratio with 95% CI were calculated using a random-effects model. Weight refers to the contribution of each study to the
pooled estimate. Squares and horizontal lines denote the point estimate and 95% CI for each study’s risk ratio. The diamond signifies
the pooled risk ratio, the diamond center denotes the point estimate, and the width denotes the 95% CI. M-H indicates Mantel-
Haenszel; and OMT, optimal medical therapy.
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Figure 4. Forest plot for major adverse cardiac events comparing revascularization vs medical therapy.
The pooled risk ratio with 95% CI were calculated using a random-effects model. Weight refers to the contribution of each study to the
pooled estimate. Squares and horizontal lines denote the point estimate and 95% CI for each study’s risk ratio. The diamond signifies
the pooled risk ratio, the diamond center denotes the point estimate, and the width denotes the 95% CI. IV indicates inverse; and
OMT, optimal medical therapy.
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from 1995 to 2001.24 Revascularization with PCI was
associated with a lower risk of death versus no revascularization in patients with end-stage renal disease,
but not in patients who were non–dialysis-dependent
with CKD. Patel et al studied 222 waitlisted transplant
candidates who underwent pretransplant cardiac assessment.25 Patients with a high index of suspicion of
CAD underwent angiography and revascularization if
indicated. There was no apparent survival difference in
patients who underwent percutaneous coronary intervention or coronary artery bypass graft surgery compared with those who were not revascularized.
Ultimately, it is important to note that the support for
preemptive revascularization to date have been based
on observational studies such as these without a
comparator group and 1 small randomized controlled
trial performed in 1992.26 At present, ISCHEMIA-
CKD (International Study of Comparative Health

Effectiveness of Medical and Invasive Approaches-
Chronic Kidney Disease) is the only large randomized
controlled trial to compare invasive revascularization
with OMT versus OMT alone in patients with CKD and
CAD.20 In a post hoc analysis from ISCHEMIA-CKD,
194 of 777 patients were transplant candidates. An
invasive strategy with preemptive revascularization
compared with conservative OMT did not improve all-
cause mortality or nonfatal MI in these patients.
There is general agreement among the kidney transplant community on the need to screen for asymptomatic CAD among transplant candidates who are at
high risk. However, how to screen for asymptomatic
CAD and whether subsequent revascularization is performed vary widely among different transplant centers.
This is despite guidance available and endorsed by the
American College of Cardiology, the American Heart
Association, the National Kidney Foundation, and the

Figure 5. Subgroup sensitivity analysis for major adverse cardiac events.
The pooled risk ratio with 95% CI were calculated using a random-effects model. Weight refers to the contribution of each study to the
pooled estimate. Squares and horizontal lines denote the point estimate and 95% CI for each study’s risk ratio. The diamond signifies
the pooled risk ratio, the diamond center denotes the point estimate, and the width denotes the 95% CI. IV indicates inverse; and
OMT, optimal medical therapy.
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American Society of Transplantation.27 The Kidney
Disease: Improving Global Outcomes clinical practice guidelines and the American Heart Association/
American College of Cardiology recommend that asymptomatic kidney and liver transplant candidates with
known CAD should not undergo routine coronary revascularization exclusively to reduce perioperative cardiac events. Rather, such therapy should be reserved
for high-risk anatomic subsets where revascularization
would allow improved survival.28,29
Two reasons may explain why revascularization
practices are so varied despite the available guidance.
First, there is a paucity of robust data on the optimal
screening and subsequent appropriate management
when CAD is found. This is unsurprising, because
patients with CKD are often excluded from major cardiovascular disease trials. Second, waitlisted patients
invariably fall into a no man’s land, where the responsibility of cardiovascular risk ownership is unclear in
the setting of a fragmented model of care consisting of
the transplant nephrologist, the evaluating cardiologist,
and the referring nephrologist.
The objective of this meta-analysis was to aid in
further clarifying whether preemptive revascularization confers a benefit over OMT in transplant candidates with CAD. Our findings demonstrate that this is
not the case. Coronary revascularization is not without
its risks. Additionally, it may delay kidney transplantation and prolong waitlist times. Ultimately, patients
may not survive long enough while on the waitlist
to be transplanted. There are also patients who are
denied a transplant if they are not revascularized,
inevitably denying them the benefits of transplantation. Although the widespread use of OMT has progressed, including the use of guideline-based statins,
β-blockers, and angiotensin II receptor blockers or
angiotensin-converting enzyme inhibitors, the use of
it in practice is still suboptimal. In the ISCHEMIA-CKD
trial, <50% of all participants were on angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors at recruitment.20 In a separate study from the
United Kingdom, the use of an interdisciplinary CKD
heart failure clinic in managing patients with CKD and
heart failure was conducted in a real-word cohort.
At recruitment, 81% of patients were on β-blockers,
but only 55% were on angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors, and
only 17% were on mineralocorticoid receptor antagonists.30 Less use of angiotensin II receptor blockers or
angiotensin-converting enzyme inhibitors in patients
with established CKD is likely because of concern
for worsening renal function and subsequent risk of
developing hyperkalemia. Ultimately, future large randomized controlled trials such as ISCHEMIA-
CKD,
which includes patients with CKD on the transplant
waitlist, and meta-analyses of studies such as these
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will help confirm the benefit of OMT over preemptive revascularization in this population. In turn, this
may help improve the use of these guideline-based
medications.

Limitations
This meta-analysis has limitations primarily because
of limitations in the studies that were included. There
was heterogeneity in the baseline characteristics of
the patients included in each study. The mean follow-up duration was 3 years, and it is possible that
longer follow-up would be required to detect differences in outcomes between the 2 groups. The specific OMT regimen used for CAD was not described
within the individual studies; therefore, it is unclear
what the composition and dosage of the medications
used were. Additionally, except for one, most studies included were observational in design and lacked
randomization, which increases the possibility of selection bias and confounding. Finally, meta-analyses
are prone to reviewer selection bias. However, this
was minimized by using the systematic Preferred
Reporting Items for Systematic Review and Meta-
Analyses guidelines to report this meta-analysis and
having 2 independent reviewers extract the data.

CONCLUSIONS
At present, there is no established protocol to determine
the optimal strategy to screen for CAD in kidney transplant candidates. Importantly, whether abnormal screening results warrant further invasive investigation, such as
coronary angiography and subsequent revascularization,
is unclear. More robust data are required before clear protocols can be established. This meta-analysis suggests
that revascularization was not superior to OMT in reducing all-cause mortality, cardiovascular mortality, or MACEs
in waitlisted kidney transplant candidates with asymptomatic CAD who eventually underwent kidney transplantation. These findings are not surprising. The cardiologist’s
approach to any preoperative ischemia evaluation is not
to find asymptomatic disease and correct it, because it is
clear that this approach does not make people feel better, live longer, or improve survival in noncardiac surgery.
The goal is to uncover left main disease for which bypass
surgery would be indicated, independent of planned noncardiac surgery. Therefore, initiating aggressive OMT and
conducting vigorous cardiac risk stratification primarily
to exclude left main disease, with close hemodynamic
monitoring perioperatively, are essential for optimizing outcomes in this high-risk population.
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